Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Intervention in Hospitalised COVID-19: Favipiravir vs Hydroxychloroquine + Azithromycin + Zinc vs Standard Care
2020-001449-38Phase 3Unknown
- Sponsor
- Chelsea and Westminster Hospital NHS Foundation Trust
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of favipiravir, hydroxychloroquine, azithromycin and zinc in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Chelsea and Westminster Hospital NHS Foundation Trust. Primary endpoint: Time to clinical improvement. Status: unknown.
02
Drugs
favipiravirhydroxychloroquineazithromycinzinc
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001449-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001449-38.